HC Wainwright Analysts Increase Earnings Estimates for RIGL

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Rigel Pharmaceuticals to $0.99 from $0.68 and maintained a Buy rating with an $85 price target. The firm projects full-year 2026 EPS of $3.26, rising to $7.95 by 2030.
• Rigel’s latest quarterly results significantly exceeded expectations, with EPS of $0.88 versus the $0.09 consensus estimate and revenue of $78.7 million compared with $55.27 million expected.
• Analyst sentiment remains mixed: four analysts rate the stock Buy, two Hold, and one Sell, producing an overall Hold consensus and an average price target of $59. Rigel shares recently opened at $42.45.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Analysts at HC Wainwright raised their Q3 2026 earnings estimates for Rigel Pharmaceuticals in a research report issued on Friday, August 14th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $0.99 for the quarter, up from their prior forecast of $0.68. HC Wainwright currently has a "Buy" rating and a $85.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $2.88 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' Q4 2026 earnings at $0.94 EPS, FY2026 earnings at $3.26 EPS, FY2027 earnings at $5.26 EPS, FY2028 earnings at $5.88 EPS, FY2029 earnings at $6.76 EPS and FY2030 earnings at $7.95 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.79. Rigel Pharmaceuticals had a net margin of 116.30% and a return on equity of 22.95%. The business had revenue of $78.70 million during the quarter, compared to the consensus estimate of $55.27 million.

Several other brokerages also recently weighed in on RIGL. Weiss Ratings upgraded Rigel Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, August 6th. Piper Sandler reissued a "neutral" rating and issued a $49.00 target price (up from $40.00) on shares of Rigel Pharmaceuticals in a report on Monday. Zacks Research lowered Rigel Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 7th. Finally, Citigroup reaffirmed a "buy" rating on shares of Rigel Pharmaceuticals in a report on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Rigel Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $59.00.

Rigel Pharmaceuticals Price Performance

RIGL stock opened at $42.45 on Tuesday. The stock has a market capitalization of $785.41 million, a price-to-earnings ratio of 2.60 and a beta of 1.16. The company has a 50-day moving average of $38.29 and a two-hundred day moving average of $33.20. Rigel Pharmaceuticals has a 52-week low of $24.95 and a 52-week high of $52.24.

Insider Buying and Selling at Rigel Pharmaceuticals

In other Rigel Pharmaceuticals news, Director Kamil Ali-Jackson sold 2,500 shares of the business's stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.00, for a total value of $87,500.00. Following the completion of the transaction, the director directly owned 10,125 shares of the company's stock, valued at approximately $354,375. The trade was a 19.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 10.47% of the company's stock.

Institutional Trading of Rigel Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. raised its position in Rigel Pharmaceuticals by 400.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 1,020 shares during the last quarter. CWM LLC increased its stake in shares of Rigel Pharmaceuticals by 217.0% in the 4th quarter. CWM LLC now owns 1,791 shares of the biotechnology company's stock valued at $77,000 after buying an additional 1,226 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Rigel Pharmaceuticals during the third quarter worth $62,000. Truvestments Capital LLC lifted its stake in shares of Rigel Pharmaceuticals by 120.3% during the fourth quarter. Truvestments Capital LLC now owns 2,207 shares of the biotechnology company's stock valued at $95,000 after acquiring an additional 1,205 shares during the period. Finally, IFP Advisors Inc boosted its holdings in Rigel Pharmaceuticals by 21.8% in the fourth quarter. IFP Advisors Inc now owns 2,264 shares of the biotechnology company's stock valued at $97,000 after acquiring an additional 405 shares during the last quarter. Institutional investors and hedge funds own 66.23% of the company's stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel's lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source